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Abstract 
Background 
Neuroblastoma (NB) tumours are commonly divided into three cytogenetic subgroups. 
However, by unsupervised principal components analysis of gene expression profiles we 
recently identified four distinct subgroups, r1-r4. In the current study we characterized these 
different subgroups in more detail, with a specific focus on the fourth divergent tumour 
subgroup (r4). 
Methods 
Expression microarray data from four international studies corresponding to 148 neuroblastic 
tumour cases were subject to division into four expression subgroups using a previously 
described 6-gene signature. Differentially expressed genes between groups were identified 
using Significance Analysis of Microarray (SAM). Next, gene expression network modelling 
was performed to map signalling pathways and cellular processes representing each 
subgroup. Findings were validated at the protein level by immunohistochemistry and 
immunoblot analyses. 
Results 
We identified several significantly up-regulated genes in the r4 subgroup of which the 
tyrosine kinase receptor ERBB3 was most prominent (fold change: 132–240). By gene set 
enrichment analysis (GSEA) the constructed gene network of ERBB3 (n = 38 network 
partners) was significantly enriched in the r4 subgroup in all four independent data sets. 
ERBB3 was also positively correlated to the ErbB family members EGFR and ERBB2 in all 
data sets, and a concurrent overexpression was seen in the r4 subgroup. Further studies of 
histopathology categories using a fifth data set of 110 neuroblastic tumours, showed a 
striking similarity between the expression profile of r4 to ganglioneuroblastoma (GNB) and 
ganglioneuroma (GN) tumours. In contrast, the NB histopathological subtype was dominated 
by mitotic regulating genes, characterizing unfavourable NB subgroups in particular. The 
high ErbB3 expression in GN tumour types was verified at the protein level, and showed 
mainly expression in the mature ganglion cells. 
Conclusions 
Conclusively, this study demonstrates the importance of performing unsupervised clustering 
and subtype discovery of data sets prior to analyses to avoid a mixture of tumour subtypes, 
which may otherwise give distorted results and lead to incorrect conclusions. The current 
study identifies ERBB3 as a clear-cut marker of a GNB/GN-like expression profile, and we 
suggest a 7-gene expression signature (including ERBB3) as a complement to histopathology 
analysis of neuroblastic tumours. Further studies of ErbB3 and other ErbB family members 
and their role in neuroblastic differentiation and pathogenesis are warranted. 
Keywords 
Microarray, Expression, Cancer, Systems biology, Oncology, Network, Reverse engineering, 
Unsupervised, Clustering, Cell cycle, Spindle assembly, Her-3, HER3, ERBB3, Her-2, 
HER2, ERBB2, EGFR, ERBB1, BIRC5, Survivin, MYCN, N-myc 
Background 
Peripheral neuroblastic tumours (NT’s) are derived from developing neuronal cells of the 
sympathetic nervous system and are the most frequent extracranial solid tumours of 
childhood. NT’s are composed of variable proportion of neuroblasts (neuronal lineage) and 
Schwannian cells (glial lineage), and are classified into histopathological categories 
according to the presence or absence of Schwannian stromal development, differentiation 
grade of the neuroblasts, and their cellular turnover index. According to the International 
Neuroblastoma Pathology Classification (INPC - Shimada system) [1], the three subtype 
categories and their subtypes are: 1) Neuroblastoma (NB), Schwannian stroma-poor; 2) 
ganglioneuroblastoma (GNB), intermixed (Schwannian stroma-rich) or nodular (composite 
Schwannian stroma-rich/stroma-dominant and stroma-poor); 3) ganglioneuroma (GN), 
Schwannian stroma-dominant. Neuroblastoma exhibit an extreme clinical and biological 
heterogeneity, and patients are assigned to risk groups based on several criteria including 
stage [2,3], age [4], histological category and grade of tumour differentiation (histopathology) 
[5], the status of the MYCN oncogene [6], chromosome 11q status [7], and DNA ploidy [8] as 
the most highly statistically significant and clinically relevant factors [9]. One-half of NB 
patients have metastatic disease at diagnosis (INSS stage 4 or INRGSS stage M). All 
metastatic tumours with MYCN amplification (MNA) are aggressive and considered being 
high-risk tumours [9], whereas children with metastatic disease without MNA (approximately 
65%) have variable clinical behaviours depending on age at diagnosis, histopathology, and 
other genetic factors. Based upon cytogenetic profiles, previous studies have categorized NB 
tumours into three major subtypes [10,11]: Subtype 1 representing favourable tumours with 
near triploidy and high expression of the Neurotrophic receptor TrkA (or NTRK1), mostly 
encompassing non-metastatic NB stages 1 and 2; subtype 2A representing unfavourable NB 
stages 3 and 4, with 11q deletion (Del11q) and 17q gain (Gain17q) but without MNA; 
subtype 2B representing unfavourable widespread NB stages 3 and 4 with MNA often 
together with 1p deletion (Del1p) and Gain17q. Several gene sets are shown to discriminate 
the molecular subgroups and risk groups by mRNA and microRNA expression profiling in 
neuroblastic tumours [12-21]. A recent expression analysis by our research group identified 
the three cytogenetically defined subtypes (1, 2A, and 2B) by unsupervised clustering, but 
further indicated the existence of a fourth divergent subgroup [12]. Moreover, we identified a 
6-gene signature including ALK, BIRC5, CCND1, MYCN, NTRK1, and PHOX2B to 
successfully discriminate these four subgroups [12]. The fourth (r4) subgroup encompassed 
tumours characterized by Del11q and high expression of genes involved in the development 
of the nervous system, but showed low expression of ALK. Approximately 7-9% of sporadic 
NB cases show inherent ALK mutations [22,23], and ALK overexpression, both in its mutated 
and wild type form, is demonstrated to define a poor prognosis in NB patients [24]. In 
relation to this our previous findings suggests the Type 2A (r2) and Type 2B (r3) subgroups, 
which both display high ALK expression, to be driven by the ALK pathway. In contrast, the 
r4 subgroup displaying low expression of all six genes of the signature, is suggested to be 
driven by an alternative oncogenesis pathway. 
In the present study we aimed to further investigate the expression profiles of the four 
subgroups, and r4 in particular. By differential expression analysis and reverse engineering 
we found ERBB3 and its network members to be significantly overrepresented within the r4 
tumour subgroup. Moreover, two other ErbB family members, ERBB2 and EGFR, were 
found to show concurrently higher expression. In contrast, unfavourable neuroblastoma 
subgroups (r2 and r3) were specifically characterized by G2/M cell cycle transition and 
mitotic regulating genes. By expression analysis of histopathology categories (i.e. NBs, 
GNBs, and GNs) we found the r4 subgroup to show an identical expression profile to 
GNB/GN types, and overexpression of ErbB3 was also confirmed at the protein level in GN 
tumours. We conclude that the ERBB-profile (high expression of EGFR, ERBB2 and ERBB3) 
defines a ganglion-rich neuroblastic tumour sub-set. 
Results 
Differential expression in r-subgroups 
To explore subgroup-specific characteristics we performed a differential expression analysis 
by SAM. Thirty-seven tumour cases from three studies were pre-processed in two separate 
data sets (data set 1, n = 14, and data set 2, n = 23, Table 1), and both data sets were divided 
into four r-subgroups based on rules according to the previously described 6-gene signature 
(6-GeneSig, Additional file 1) [12]. Six SAM pair-wise comparisons between r-subgroups 
were performed on each data set separately, and the 1000 most significant genes (according 
to descending SAM d-score) with a fold change above 2, were extracted to create SAMintersect 
gene lists representing both data sets (Additional file 2). The r2 versus r1 group comparison 
showed 122 differentially expressed genes present in lists from both data sets, and the r3 
versus r1 group comparison showed 496 overlapping genes (Figure 1A). The r4 subgroup 
showed the highest proportion of significant differentially expressed genes compared to all 
the other subgroups in both data sets (number of overlapping genes ranging between 503 and 
669, Figure 1A). 
Table 1 Data sets used in the current study 
 Name Reference # Total cases Description Analysis platform # Analysis cases Analysis groups Purpose of study 
Data set 1 DePreter [53] 17 Neuroblastoma Affy HU133A (pre-amplified) 14 r-groups (r1-r4) Differential mRNA expression of subgroups 
Data set 2 McArdle [54] 22 Neuroblastic Affy HU133A 17 r-groups (r1-r4) Differential mRNA expression of subgroups 
 Wilzén [55] 8 Neuroblastoma Affy HU133A 6 r-groups (r1-r4) Differential mRNA expression of subgroups 
Data set 3 Wang [56] 101 Neuroblastoma Affy HGU95Av 67 r-groups (r1-r4) Verification of subgroup findings; Gene network 
construction 
Data set 4 Versteeg [57] 110 Neuroblastic Affy HU133plus2 110 histology groups (GN, GNB, NB) Differential mRNA expression of histology subgroups 
Data set 5 Kogner - 12* Neuroblastic IHC, WB 8 (IHC), 9 (WB) histology groups (GN, NB) Protein expression validation in histology subgroups 
SAM Significance Analysis of Microarray. Neuroblastic = mixed pool of neuroblastoma (NB), ganglioneuroblastoma (GNB), and ganglioneuroma (GN). Affy Affymetrix, IHC 
Immunohistochemistry, WB Western blotting.* One case overlaps with data set 2 (case "NBS1" in data set 2 = case ′6′ in data set 5). 
Figure 1 Analyses of SAM gene lists. A. Venn diagram of SAM results. SAM results from 
six r-group comparisons are presented for the DePreter and McArdle/Wilzén data sets. # 
cases = Total number of cases included in each comparison from each data set; # overlapping 
genes = Total number of genes overlapping between the original SAM gene lists (1000 genes 
from each direction) from data set 1 and 2, constituting the SAMintersect gene lists; # 
significant genes = Total number of overlapping significant genes (combined p-value) using a 
cut-off of p < 6.25E-06, which correspond to a Bonferroni corrected p-value of p < 0.05; # 
genes FC > 5 = Total number of overlapping genes showing a combined fold change (FC) 
above 5 in each comparison. B. Venn diagram of GO functional themes. The Biological 
Networks Gene Ontology (BiNGO) tool in Cytoscape was utilized to map the predominant 
functional themes of the SAM gene lists. The most dominating Gene Ontology (GO) terms 
from each SAM comparison are presented from two differential expression directions; "up" 
(left panel) or "down" (right panel). Upper panel: r-group comparisons from all three data 
sets; data set 1 (DePreter), data set 2 (McArdle/Wilzén), and data set 3 (Wang). Lower panel: 
Histopathology group comparisons in data set 4 (Versteeg) The full GO search results are 
presented in Additional file 3. C. Gene network frequencies. The heat map table represents 
the percentage of network genes out of the total number of genes in the gene networks 
(marked in grey). The total number of genes in the SAM gene lists are presented to the right. 
The upper panel “Data sets 1 & 2_comb” represents combined intersect gene lists from the 
two data sets, and the other panels represents gene lists from the 1000 most differentially 
expressed genes in each direction. 
The r1 subgroup (corresponding to the cytogenetically defined subgroup Type 1) was found 
to mainly involve nervous system developmental and catecholamine metabolic process 
related genes. In the MNA-specific subgroup r3 (corresponding to Type 2B), KIF15 was the 
most significantly up-regulated gene (fold = 15) while CUX2 showed the highest expression 
fold change (fold = 17). The MYCN gene was found on the 74th position of up-regulated 
genes (fold = 9), and NTRK1 was identified as the most significantly down-regulated gene 
within r3 compared to r1 (fold = 80, Additional file 2). Also, LMO3 and PHGDH were found 
to be specifically up-regulated in the r3 subgroup compared to the other subgroups. High 
expression of ALK was found in both the r2 (2-fold) and r3 (5-fold) subgroups compared to 
the favourable r1 subgroup. Moreover, r2 and r3 also showed up-regulation of several G2/M 
cell cycle transition and mitotic checkpoint related genes (e.g. AURKA, BRCA1, BUB1B, 
CCNA2, CCNB1, KIF15, MCM2, MCM3, and MCM5 etc.), which in contrast showed a 
significant down-regulation in the r4 subgroup. In line with this, a Gene Ontology (GO) 
search identified “cell cycle” as the most significant process accumulated in the SAMintersect 
gene lists of the r2 and r3 subgroups (Figure 1B, Additional file 3). The apparent 
overrepresentation of cell cycle-related genes in subgroups r2 and r3 encouraged us to 
investigate enrichment of other cell cycle key players and networks in our SAM gene lists. 
Differential expression in subgroup r4 
Among the 10 most significantly up-regulated genes in the r4 subgroup in data sets 1 and 2, 
the following eleven genes were found; ABCA8, APOD, ASPA, CDH19, ERBB3, FXYD1, 
ITIH5, MAL, PLP1, S100B, and ST6GALNAC2. According to the GO search, these genes are 
mainly involved in nervous system development, multicellular organismal development, and 
response to wounding (Figure 1B, Additional file 3). ERBB3 was found as the “top-one” up-
regulated gene in r4 versus r3 with a 240-fold expression. ERBB3 encodes a transmembrane 
tyrosine kinase receptor, which has previously been associated with cancer in a large number 
of studies (>500 publications). ErbB3 is activated through dimerization to one of its four 
structurally related family members; EGFR, ErbB2, or ErbB4. ErbB-family members are 
often co-expressed, and thus we found it relevant to investigate their expression level 
relationships in our four neuroblatic data sets. We found a positive significant correlation of 
ERBB3 to the EGFR and ERBB2 family members, and a negative correlation to all genes of 
the 6-GeneSig in all four data sets (p < 0.05, Additional file 4). Also, EGFR and ERBB2 
showed a significant up-regulation in r4 subgroups of most data sets (p < 0.05, Additional file 
2). ERBB3 show several similarities to the ALK, encoding the NB familial gene [25], and thus 
made a good candidate gene with potential role in the tumour development of r4 tumour 
types. 
Among the down-regulated genes in the r4 subgroup CACNA2D3 was the most significant in 
comparison to the r1 subgroup (50-fold change). This gene was also found to be the 25th 
most down-regulated gene in the r3 subgroup compared to r1 (Additional file 2). Since both 
the r3 and r4 subgroups are previously found to show unfavourable outcome and poor 
survival [12], and the CACNA2D3 gene is located in the 3p21.1- locus commonly deleted in 
many NB tumours, this encouraged us to further screen the SAMintersect gene lists for other 
conceivable and previously reported tumour suppressor (TS) candidate genes. Out of 33 
previously reported TS candidate genes, 15 were present among the SAMintersect gene lists 
from data sets 1 and 2 (Additional file 5). 
Gene network construction and gene set enrichment analysis (GSEA) 
Network modelling reveals the regulatory relationships among genes and can provide a 
systematic understanding of molecular mechanisms underlying biological processes. A 
variety of algorithms have been developed, and in the current study we chose the ARACNE 
algorithm [26] for reconstruction of seven networks (ALK, BIRC5, CCND1, ERBB3, MYCN, 
NTRK1, PHOX2B) from the Wang data set (n = 102), since this method has a documented 
high performance [27]. Also, 4850 pre-existing curate gene sets (c2) from the Molecular 
Signatures Database (MSigDB) were selected (Additional file 6). We subsequently analysed 
the lists of differential expressed genes for enrichment of these 4857 gene networks. The 
SAMintersect lists of genes up-regulated in the r4 group were found to comprise 17 out of 38 
genes (~ 45%) of the ARACNE_ERBB3 network (Figure 1C), which was also verified by 
GSEA (p < 0.001, Figure 2, Additional file 7). A relatively large fraction (between 20% and 
58%) of the ARACNE_BIRC5 network partners (n = 45, Additional file 6) were found 
among the up-regulated genes of r2 and r3 tumour subgroups, which was also significant by 
GSEA (p < 0.001, Additional file 7). A GO search of the BIRC5 network partners suggested 
a role in mitosis (GO terms: cell cycle, nucleosome assembly, chromatin assembly, protein-
DNA complex assembly, nucleosome organization, mitotic cell cycle, cell cycle phase, DNA 
packaging, M phase, and cell cycle process, data not shown). Other cell-cycle or mitotic 
related gene sets found to be enriched among the r2 and r3 subgroups were e.g. 
ZHOU_CELL_CYCLE_GENES_IN_IR_RESPONSE_24HR, 
WHITFIELD_CELL_CYCLE_LITERATURE, REACTOME_CELL_CYCLE_MITOTIC, 
REACTOME_CELL_CYCLE_CHECKPOINTS curate gene sets (Additional file 7). 
Figure 2 Analyses of the ERBB3 gene network. Gene network of ERBB3 (n = 38) for all 
data sets showing differentially expressed genes of r-groups (data sets 1–3) and 
histopathology groups (data set 4). Nodes are coloured as follows: Red = Up-regulated, 
Green = Down-regulated, Grey = Not affected. Upper panel: Data sets 1 and 2 (DePreter and 
McArdle/Wilzén) presenting three r-group comparisons (r4 vs. r1, r4 vs. r2, and r4 vs. r3). 
Only genes that were common in both data set 1 and 2 with fold change > 2 were included 
(i.e. SAMintersect gene lists). Middle panel: Data set 3 (Wang) presenting three r-group 
comparisons (r4 vs. r1, r4 vs. r2, and r4 vs. r3). Genes included were those present in SAM 
gene list representing the 1000 most differentially expressed with fold change > 2 (ranked 
after significance). Lower panel: Data set 4 (Versteeg) presenting two histopathology group 
comparisons (GNB vs. NB and GN vs. NB). Genes included were those present in SAM gene 
list representing the 1000 most differentially expressed (ranked after significance). Gene set 
enrichment analysis (GSEA) plots of the ERBB3 network are according to gene list sorting 
mode = real, sorted in descending order. NES = Normalized enrichment score, NOM p-val. = 
Nominal p-value, according to the GSEA results (see Additional file 6). 
Verification of gene network modelling and differential expression analysis 
The differential expression profiles of the r-subgroups were verified by replicating the study 
using the Wang data set (n = 67 cases, Table 1). The outcomes of SAM were in consistence 
with previous findings, showing the ERBB3 gene to be significantly up-regulated and its 
gene-network partners to be significantly overrepresented in the r4 subgroup (Figure 1C, 
Figure 2). Also, several other previously identified r4-specific genes, APOD, CDH19, 
FXYD1, and S100B, were found among the 1000 most significantly up-regulated genes. In 
concordance with the previous analysis, we found the expression of CUX2 (fold = 5), LMO3 
(fold = 2.7) and PHGDH (fold = 1.9) to be significantly higher in the MNA subgroup (r3) 
compared to the favourable subset (r1). In addition, cell cycle-related genes dominated the r2 
and r3 subgroups and this was significantly proven by GSEA of the BIRC5 network, and 
other cell cycle networks (p < 0.001, Additional file 7). 
To confirm the robustness of the ARACNE constructed gene networks, we selected the r3 
versus r1 comparisons in data sets 1 and 2 to investigate the expected overrepresentation of 
MYCN- and NTRK1-networks. Fourteen genes out of 40 (35%) of the ARACNE_MYCN 
network were found in the up-regulated gene lists, while eight out of 40 (20%) genes were 
found in the down-regulated gene lists, demonstrating an accumulation of the 
ARACNE_MYCN network in the r3 subgroup (Figure 1C, Additional file 7). Also, an 
accumulation of the ARACNE_NTRK1 network was found in the opposite direction. Out of 
62 genes composing the ARACNE_NTRK1 network, 28 genes (~ 45%) were among the 
1000 most down-regulated genes in r3, which was significant by GSEA (Additional files 6 
and 7). According to significance by SAM, the NTRK1 gene was the “top-one” down-
regulated gene within the r3 versus r1 subgroup comparison in both data sets (fold change: 
>70, Figure 1C, Additional file 2). From these facts we conclude our study design to be 
substantial, and the constructed gene networks by ARACNE to be reliable and highly 
representative to what has been previously reported. 
In addition, we checked the enrichment of network partners to the 6-GeneSig (ALK, BIRC5, 
CCND1, MYCN, NTRK1, and PHOX2B) and found the network representations to be in 
concordance with the 6-GeneSig expression levels in r-subgroups (Additional file 7). The 
credibility of ARACNE constructed networks were also tested by literature verification, and 
seven out of 38 transcriptional connections of the ERBB3-network as well as 11 out of 40 
transcriptional connections of the MYCN-network were verified to have a functional 
relationship (data not shown). This demonstrates the robustness of the computationally 
inferred network analysis. 
Differential expression analysis of histopathology groups (data set 4) 
To further explore the ERBB3 expression among other neuroblastic tumour we utilized the 
R2 database (www.R2.amc.nl), and found indications of high ERBB3 expression in GNB and 
GN tumours. To investigate this finding in more detail, we performed a differential 
expression analysis of the histopathology subtypes in the Versteeg 110 data set (n = 110, 
Table 1). As expected, the ERBB3 gene and networks partners were significantly enriched in 
GNB and GN tumours compared to NB (Figure 1C, Additional file 7). The highest 
enrichment of the ERBB3-network was found in GN tumours, with 18 up-regulated genes out 
of 38 (p < 0.001, Figure 2). In contrast, cell cycle-related genes and gene networks 
significantly dominated the NB types, including the ARACNE_BIRC5 network (Additional 
files 2 and 7). 
Subgroup-specific expression profiles 
ErbB family member genes (ERBB-genes; EGFR, ERBB2, and ERBB3) and 15 previously 
reported tumour suppressor candidate genes (TS-genes) were next studied by heat maps in all 
four data sets (Figure 3). Most TS candidate genes showed down-regulation in the MNA-
specific r3 subgroup only. However, the CTNNBIP1 and KIF1B transcripts were also found 
to be down-regulated in both r3 and r4 subgroups, and the TFAP2B transcript was 
specifically down-regulated in the r4 subgroup alone (Figure 3, Additional file 2). Overall, 
the expression profiles of the 6-GeneSig genes, ERBB-genes, and TS-genes (25 genes in 
total) among r-subgroups were very similar between data sets. Moreover, the expression 
profiles of the GNB/GN showed an identical profile to the previously detected r4 subgroups 
of NB (Figure 3). These results strongly indicate that the same cellular pathways are active in 
r4 and GNB/GN tumours types, hence the ERBB-gene profile most likely represents a more 
differentiated subset of tumours. 
Figure 3 Heat maps of r-subgroups. Heat map of the 6-GeneSig (ALK, BIRC5, CCND1, 
MYCN, NTRK1, and PHOX2B), ERBB-genes (EGFR, ERBB2, and ERBB3) and 15 TS-genes 
(Tumour suppressor candidate genes) for all four data sets. The heat map colour scale is 
based on standard deviations (sd) of all cases in each data set separately, and ranges from sd 
= 2 (red) to sd = −2 (green). The lower panel represents clinical and biological markers: 
Histopathology, NB = Neuroblastoma, GNB = ganglioneuroblastoma, GN = ganglioneuroma; 
Stage INSS, clinical stages 1–4, and 4S according to the international staging system, na = 
not available; Event = dead of disease, MNA = MYCN amplification, Del1p = 1p deletion, 
Del11q = 11q deletion, Gain17q = gain of 17q. Colour coding: white = no event, black = 
event, grey = not available. 
Verification of ErbB3 at protein level (data set 5) 
To validate the biological significance of the ERBB3 enrichment in the expression profiles of 
GN tumours, the ErbB3 protein expression was investigated by immunohistochemistry (IHC) 
and western blot (WB) analysis. The IHC was performed on formalin-fixed and paraffin-
embedded (FFPE) tissue slides from four GN and four NB tumours by using antibodies 
specific for Sox10 ([N-20], Santa Cruz Biotechnology) and ErbB-3 ([RTJ2], Abcam) 
respectively. The IHC showed ErbB3 to be mainly expressed in mature ganglion cells, 
whereas Sox10 was expressed in both ganglion and schwannian cells (Figure 4A-B). 
Figure 4 Protein expression validation of ErbB3. A. Immunohistochemistry (IHC) 
assessment of case 2 showing ErbB3 expression in the mature ganglion cells, and Sox10 
expression in both ganglion and schwannian cells. Tumour tissue sections were stained using 
horseradish peroxidase (HRP) secondary antibodies. The right panel shows the Sox10 and 
ErbB3 expression results from all IHC assessments performed, y = yes, n = no expression. B. 
Colocalization study of ErbB3 and Sox10, showing ErbB3 expression mainly in ganglion 
cells. Tumour tissue sections were simultaneously fluorescently stained using anti-goat Alexa 
Fluor 594 (Sox10, red) and anti-mouse Alexa Fluor 488 (ErbB3, green), and Dapi (DNA, 
blue). C. High protein levels in GN tumours shown by Western blot of ErbB3. Primary 
antibodies used in studies: Sox10 ([N-20], Santa Cruz Biotechnology), and ErbB-3 ([RTJ2], 
Abcam), which binds to both phosphorylated and unphosphorylated forms. Case 6 was also 
included in the microarray analysis (NBS1, data set 2). Clinical data: NB = neuroblastoma, 
GNB = ganglioneuroblastoma, GN = ganglioneuroma; INSS stage [2]; INRGSS stage [3]: L 
= Localised, L1/L2 (INSS 1, 2, 3); M = Metastatic (INSS 4); Outcome: NED = No evidence 
of disease (white); AWD = Alive with disease (grey); DOD = Dead of disease (black); MNA 
(MYCN-amplification), black = yes, white = no, na = not applicable. 
Immunoblot analysis was performed on five GN and four NB in total (data set 5, Table 1). 
Out of the five investigated GN cases, four corresponded to the GN cases examined by IHC. 
In addition, the WB analysis also included one NB encompassed in the microarray analysis 
(case 6 corresponding to NBS1 in data set 2). The same antibody as for IHC ([RTJ2], Abcam) 
directed against the cytoplasmic region of ErbB3 was chosen to detect several isoforms of the 
protein as well as post-translationally modified and unmodified forms. Overall, ErbB3 
expression levels were high and clearly enriched in the GN subset compared to the NB 
subset, which showed no detectable levels of ErbB3. Moreover, case 6/NBS1 previously 
displaying no or very low expression of ERBB3 by microarray analysis (data set 2, Figure 3), 
showed no detectable levels of ErbB3 at protein level by immunoblot analysis. Only one of 
the NB tumours (case 9) showed a strong ErbB3 signal. However, this case was a localized 
INSS stage 3 with favourable biology, later histopathologically classified as a GNB. The IHC 
assessment showed that a high fraction of mature ganglion cells, satellite cells, as well as 
schwannian cells were Sox10 immunopositive (data not shown). Moreover, only the lower 
molecular weight band was visible indicating that the protein might be in its inactive 
unphosphorylated form, or indicate other post-translational modification or isoforms of 
ErbB3 (Figure 4C). 
Histopathology classification 
Based on our results we included ERBB3 in the 6-GeneSig thus creating a new 7-GeneSig. 
The 7-GeneSig was refined to discriminate five subclasses; “NB-r1”, “NB-r2”, “NB-r3”, 
“GNB-r4”, and “GN-r4” (Additional file 9). In order to test the robustness of this 7-GeneSig 
subgroup classifications, cases from all data sets were reclassified into three histopathology 
prediction classes “NB” (NB-r1, NB-r2, NB-r3), “GNB” (GNB-r4), and “GN” (GN-r4) and 
the reliability of assignments were investigated. Out of 110 neuroblastic tumours of the 
Versteeg data set, 82 cases could be successfully assigned according to the 7-GeneSig rules 
(Additional file 9). All NB histopathology types (64 out of 64) were correctly assigned 
according to the 7-GeneSig, and the inter-rate reliability of assignments was highly 
significant (Kappa measure of agreement p = 7.489E-17, Table 2). Five out of eight GNB 
tumour types, as well as nine out of ten GN tumour types were correctly assigned. One GN 
was predicted as “GNB” according to the 7-GeneSig (Table 2). In addition, we also 
performed a reassignment test on data set 2 comprising one GN, four GNB, and 25 NB 
tumour types, which was also significant (inter-rate reliability p = 0.003, data not shown). 
Reassignment of r4-cases (from data sets 1, 2 and 3), previously classified as NB, were all 
assigned to the “GNB” or “GN” categories by the 7-GeneSig (Figure 3). Also, all NB cases 
of data set 4 fell into the NB r1-r3 categories (data not shown). Conclusively, the 
histopathology classification and subgroup assignment by the 7-GeneSig seemed reliable and 
highly predictive. 
Table 2 Histology prediction by 7-GeneSig 
Histology 
NB GNB GN Total: 
Predicted 
NB 64 0 0 64 
GN 0 1 9 10 
GNB 2 5 1 8 
 
Total: 66 6 10 82 nd=28 
Measure of agreement (Kappa) p= 7.489E-17 
Histology prediction was performed on the Versteeg data set (n = 110). Group prediction was based upon the standard 
deviation (sd) of expression of ALK, BIRC5, CCND1, MYCN, NTRK1, PHOX2B, and ERBB3 according to the rules in 
Additional file 9. Out of 110 tumours, 82 were successfully assigned and for 28 tumour cases no group belonging could be 
determined. The groups were assigned as follows: "NB" (r1-r3),"GNB" (r4-GNB), and "GN" (r4-GN). The inter-rate 
reliability (Kappa) was used to measure the agreement between the assignments of categories (p= 7.489E-17). 
Discussion 
Neuroblastic tumours (NT’s) represent a spectrum of disease, from undifferentiated and 
aggressive NB to the differentiated and largely quiescent GN tumours. NB tumours are 
commonly categorized into three main types based on numerical and structural genomic 
alterations, as well as expression of the neurotrophin receptor TrkA [10]. In a recent study 
using Principal Components Analysis (PCA) however, our data indicated the existence of 
four molecular tumour groups, r1-r4 [12]. In the current study we aimed to further 
characterize these four molecular subgroups, and investigated the divergent r4 group in 
particular. While the r2 (Type 2A) and r3 (Type 2B) tumour subgroups were dominated by 
cell cycle-related genes and networks, those were completely absent in the r4 subgroups (data 
sets 1–3) and GNB or GN subtypes (data set 4). The vast majority of the cell cycle-related 
genes were linked to the G2/M transition and spindle assembly checkpoint (e.g. BIRC5, 
BRCA1, BUB1B, CCNA2, CCNB1, FANCI, HMMR, KIF15, and MCM2), many of which 
were found to belong to the ARACNE-modelled BIRC5-network. Overexpression of genes 
involved in mitotic regulation is typical for rapidly proliferating tumours and would also be 
expected to be enriched in the aggressive NB subtypes when compared to more differentiated 
quiescent GNB and GN tumours. The BIRC5 protein is found to stabilize the microtubules in 
the chromosomal passenger complex, and knockdown of BIRC5 causes apoptosis in NB via 
mitotic catastrophe [28]. Also, a previous publication show that NB tumours with genomic 
aberrations in G1-regulating genes leads to S and G2/M phase progression [20]. Interestingly, 
the fork head box (FOX) gene FOXM1 encoding a protein phosphorylated in M phase was 
significantly up-regulated in r2 and r3 subgroups. FOXM1 activates the expression of several 
cell cycle genes, e.g. AURKB, CCNB1, CCND1, MYC, and is involved in cell proliferation 
and malignancy [29]. Several cell cycle and DNA repair genes, including BIRC5, are 
suggested to act downstream of N-myc [21,30,31]. In addition, most of the studied tumour 
suppressor (TS) candidates were specifically down-regulated in the r3 subgroup, which is 
probably explained by them acting downstream of N-myc. Several of the TS candidate genes 
are also located in the 1p36 chromosomal region (e.g. CHD5 and KIF1B [32-34]), and Del1p 
is a well-known prognostic marker highly correlated to MYCN-amplification in NB [35]. One 
such N-myc-regulated and 1p36-localized TS candidate is CDC42, encoding a small GTPase 
protein. This protein have a function in cell polarization and growth cone development in NB 
cell differentiation, similar to Rac1 and Cux-2, and is suggested to inhibit neuritogenesis in 
NB [36]. In concordance to this, we found CDC42 to be the 14th most significantly down-
regulated gene in the MNA subgroup (r3) compared to subgroup r2. 
The main focus of the study was to define the underlying regulatory networks of the r4 
subgroup. In contrast to the other three well-known subgroups of NB, the r4 tumours showed 
high expression of embryonic development and nervous system signalling genes. One of the 
most prominent genes from the differential expression analysis was ERBB3, encoding a 
member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases 
(RTK’s). The ARACNE-modelled ERBB3-network was significantly enriched in the 
differentially expressed gene lists of the r4 subgroups (data sets 1-3), and this enrichment was 
also found in the GNB and GN histopathology categories of data set 4. Two members of the 
ERBB3-network, S100B and SOX10, were among the ten most significantly up-regulated 
genes in the r4 subgroups. The S100 calcium binding protein B (S100B) has long been 
reported as a prognostic biomarker of malignant melanoma [37], and a paired down-
regulation of ERBB3 and S100B is observed in malignant peripheral nerve sheath tumours 
confirming their functional relationship [38]. Interestingly, the S100beta protein, mapping to 
chromosome 21, has been proposed to be responsible for the lack of NB in Down syndrome 
patients by producing growth inhibition and differentiation of neural cells [39]. The SRY box 
10 transcription factor (Sox10) is a key regulator of the developing nervous system, and has 
been shown to control expression of ErbB3 in neural crest cells [40,41]. A paired 
overexpression of ErbB3 and Sox10 has been observed in pilocytic astrocytoma (PA) a 
common glioma of childhood, which verifies their network connection found in the current 
study [42]. Also, Sox10 and S100 are routinely employed in the pathological diagnosis of 
neural crest-derived tumours [43], and Sox10 serves as an embryonic glial-lineage marker in 
NT’s [44]. By immunohistochemistry assessment, we found Sox10 to be expressed in both 
the schwannian cells and ganglion cells, whereas ErbB3 was found mainly in the mature 
ganglion cells. We could also verify the GN-specific expression of ErbB3 by immunoblot 
analysis. 
ErbB3 is activated through ligand binding of neuregulin (NRG), leading to 
heterodimerization of ErbB3 to other ErbB members and subsequent phosphorylation. 
Activated ErbB3 regulates proliferation through downstream signalling of the 
phosphoinositol 3-kinase/AKT survival/mitogenic pathways [25]. In the current study we 
found a significant correlation of ERBB3 to its family members EGFR and ERBB2 in all four 
independent data sets. EGFR and ERBB2 were also both found to be significantly up-
regulated in all r4 subgroups as well as in the GNB and GN tumours. Amplification of 
ERBB3 and/or overexpression of its protein has been reported in numerous cancers, including 
prostate, bladder, and breast. Moreover, loss of ErbB3 function has been shown to eliminate 
the transforming capability of ErbB2 (also known as HER-2) in breast tumours [45]. 
Although the extent of the role of ErbB3 is emerging, its clinical relevance in different 
tumours is controversial. There are a few studies of ErbB/HER receptor expression in 
neuroblastoma, showing that ErbB/HER family members in neuroblastic tumour biology is 
interrelated and complex, but their expression level may present a prognostic factor for 
patients outcome [46-48]. 
The heat map of 25 genes including the 6-GeneSig genes, ERBB-genes and TS-genes showed 
a very specific expression pattern among the different r-subgroups and histopathology 
categories. The similarity of expression profiles between the four data sets was striking. The 
correspondence of the r4 subgroups to the GNB and GN histopathology subtypes was 
obvious, and ERBB3 appeared as a clear-cut marker for a GNB/GN-like expression profile. 
To demonstrate this further, a new 7-GeneSig (including ERBB3) was constructed and used 
in a histopathology reassignment classification test. The 7-GeneSig successfully assigned 
100% NB tumours, 62,5% GNB tumours, and 90% GN tumours into the correct 
histopathology category (Kappa measure of agreement p = 7.489E-17, data set 4). Also, all 
r4-tumour types from data sets 1–3 were categorized as GNB or GN tumours according to the 
7-GeneSig. By these facts we conclude that the NB tumours previously assigned to the r4 
subgroup by the 6-GeneSig, most likely represent more differentiated NT’s and are 
seemingly GNB/GN tumours types. Our study brings out the complexity in classifying 
neuroblastic tumours. The previously described unfavourable characteristics and poor 
outcome of the r4 tumour group is puzzling [12], but can be explained by the fact that 
prognostic subsets of GNB’s exist [49]. Historically, GNB’s have been the most difficult of 
the NT’s to define in a consistent and uniform fashion, because the number and degree of 
differentiation of the neuroblastic cells tend to vary between cases as well as between 
different microscopic fields in the same tumour [1]. Moreover, the data sets used in the 
current study are probably not truly population-based, and the r4 subgroups found in different 
data sets probably consist of different proportions of F/UF subsets. In addition, some tumours 
may previously have been misclassified as NB, or the tumour tissue part analysed by 
microarray may not be the same as the tissue that underwent histopathology assessment. 
Furthermore, it is not clear whether differentiation markers are superior to other prognostic 
factors in defining outcome. Unfavourable markers such as MNA and clinical stage may also 
be present in differentiated cells, and mark a poor prognosis by themselves. 
ErbB3 also has an important role in differentiation of Neural crest cell (NCC) lineages during 
the embryonic development [50]. Although ErbB receptors are also found to mediate 
proliferation and survival [47,48], the ERBB-profile found in this study is likely to reflect the 
phenotype or differentiation stage of developing neuronal progenitors. Upon induction of 
differentiation, neuronal progenitors may follow a variety of stages of neural crest cell 
lineages. For example, neuroblasts in culture are shown to represent an immature bilineage 
stage able to progress towards neuronal and glial fates [44]. Schwannian cells are the 
principal glia of the peripheral nervous system, whereas neuroblasts differentiate from neural 
stem cells and exhibit variable degrees of differentiation up to ganglion cells. In this context, 
the ERBB-profile seems to be a marker of ganglionic-neuronal differentiation. A recent 
immunohistochemistry study of ErbB2 in neuroblastic tumours supports this conclusion [51]. 
However, it still remains uncertain whether the r4 subgroup of datasets 1 and 3 are indeed 
GN or GNB, or if the ERBB expression profile just marks the gradually differentiated NB 
tumours (encompassing increased levels of mature ganglion cells). Nevertheless, the results 
from all data sets are consistent in regards to the expression profile of the 25 genes selected 
for the heat map, strengthening the robustness of the suggested 7-gene signature. 
Accordingly, we propose ErbB3 as an excellent marker of neuronal differentiation, and 
suggest mRNA expression profiling by the 7-gene signature as a complement to 
histopathological assessment. However, the exact cut-off expression levels for classification 
needs to be worked out in more detail, and classification must be based on international 
standard cases and assays. 
Conclusions 
In summary, by differential expression analysis and network modelling we have identified 
genes and gene networks constituting molecular and histological subgroups of neuroblastic 
tumours. The primary aim of our study was to identify genes characterizing the previously 
unknown r4 subgroup. Our results pinpointed ERBB3 and its network as one of the most 
significantly up-regulated genes within this group. By studying the expression profiles in a 
broader range of neuroblastic tumour types, we found the r4 subgroup to be highly similar to 
GNB/GN tumour types. The ERBB-dominating profile found in r4 and GNB/GN tumours 
was clearly divergent from the cell-cycle-dominating profile mainly representing NB tumour 
subgroups (specifically unfavourable NB subgroups). Our findings indicate that the 
previously identified r4 subgroup most likely constitutes GNB/GN tumours or NB tumours 
with high content of mature ganglion cells. This study also demonstrates the importance of 
performing unsupervised subtype clustering prior to down-stream analyses. Predefined 
subgroups and supervised clustering studies might give distorted results if they are based on 
pools of mixed tumour histopathology subgroups. In conclusion, we have identified ERBB3 
as a marker of a GNB/GN-like expression profile, and we suggest a 7-gene expression 
signature as a complement to histopathological assessment of neuroblastic tumours. Further 
studies of ErbB3 and other members of the ErbB family and their role in neuroblastic 
differentiation and pathogenesis are warranted. 
Methods 
Pre-processing microarray data 
Data from five published neuroblastoma expression microarray studies run on three different 
Affymetrix platforms (HU133A, HGU95Av, and HU133plus2) were used in this study 
(Table 1). Raw data files were obtained from Array Express (www.ebi.ac.uk/microarray-
as/ae/) and Gene Expression Omnibus (www.ncbi.nlm.nih.gov/geo/), or directly from 
collaborators. Expression data files were normalized by gcRMA using Bioconducter (library 
BioC 2.4) in R 2.9.2 [52] in four separate groups; 1) the De Preter [53] data set run on the 
HGU133A Affymetrix platform (17 samples, preamplified), 2) the McArdle [54] and the 
Wilzén [55] data sets run on the HGU133A Affymetrix platform (30 samples, not pre-
amplified), 3) the Wang [56] data set run on the HGU95Av2 platform (102 samples, not pre-
amplified), and 4) the Versteeg [57] data set run on the HU133plus2 platform (110 samples). 
For each probe-set, the maximum expression values over all samples were determined, and 
probe-sets which showed very low or no detectable expression levels were filtered out (log2 
expression <5). Next, the mean log2 expression level for each Gene symbol was calculated to 
generate “mean-per-gene” data files: 7439 genes in data set 1, 8106 genes in data set 2, 7542 
genes in data set 3, and 15614 genes in data set 4. 
Differential expression analysis 
NB samples from the DePreter and McArdle/Wilzén data sets were divided into four r-
subgroups by a 6-gene signature (further referred to as the“6-GeneSig”) according to Abel et 
al., 2011 [12] (Additional file 1). From these two data sets, 14 (preamplified, De Preter) and 
23 (non-preamplified, McArdle/Wilzén) cases respectively were successfully assigned into 
one of the four r-groups (Table 1). Differential gene expression analysis was performed by a 
two group unpaired Significance Analysis of Microarray (SAM) test (i.e. six comparisons) 
[58]. Gene lists comprising the 1000 most significantly differentially expressed genes (sorted 
after the d-statistic) with a fold change above 2 were exported from each comparison, from 
each direction (up or down), and from each data set, separately (resulting in 12 SAM gene 
lists per data set). Next, SAM gene lists from the two different data sets were compared, and 
12 intersection gene lists (SAMintersect) were created. Too minimize the variance, a combined 
fold change (FCcomb) for each gene in the SAMintersect gene list was calculated as follows: 
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where SEi is the standard error of the mean log2 expression values in data 
set i. 
A combined p-value (Pcomb) for each gene in the SAMintersect gene list was calculated as 
follows: 
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where Ni is the total number of samples of the two groups compared by the 
d-statistic in SAM, and Pi the corresponding p-value for dataset i. Φ is the cumulative 
distribution function of the standard normal distribution and Φ-1 is its inverse function. 
Based on an approximation of 8000 multiple tests (i.e. 8000 genes), a nominal p-value 
<6.25E-06 was found to correspond to an adjusted p-value <0.05 (according to Bonferroni 
correction) and was subsequently used as a cut-off for significance in SAM. 
Gene network modelling 
A large gene regulatory network was constructed from an independent data set (Wang) of 102 
expression profiles [56]. Mutual information values were estimated with the ARACNE 
(Algorithm for the Reconstruction of Accurate Cellular Networks) algorithm using a p-value 
cut-off of 1E-7 [26]. The data processing inequality (DPI) was applied with a tolerance of 
0.15. Gene networks of seven selected genes were extracted from the global network together 
with their immediate gene neighbours. The gene networks of nearest neighbours were 
visualized in Cytoscape 2.8.2. 
Gene ontology (GO) and Gene Set enrichment analysis (GSEA) 
Ranked (by d-statistic) SAM gene lists from the separate data sets were investigated for Gene 
Ontology terms using BiNGO 2.4 (Biological Network Gene Ontology, 
www.psb.ugent.be/cbd/papers/BiNGO/ ). The Gene Set Enrichment Analysis (GSEA, 
www.broad.mit.edu/gsea/) software was used to investigate whether a gene network was 
significantly overrepresented in the different r-subgroups. The enrichment tests were 
performed using seven ARACNE-constructed gene networks ALK (n = 12 genes), BIRC5 (n 
= 45 genes), CCND1 (n = 22 genes), ERBB3 (n = 38 genes), MYCN (n = 40 genes), NTRK1 
(n = 62 genes), and PHOX2B (n = 67 genes), as well as 4850 MSigDB-curated gene sets (c2, 
www.broadinstitute.org/gsea/msigdb/index.jsp, Additional file 6). The GSEA according to 
Subramanian et al. [59], was run on the “mean-per-gene” data files using the following 
settings: number of permutations = 1000, permutation type = gene-set, chip platform = 
GENE_SYMBOL.chip, enrichment statistic = weighted, metric for ranking genes = 
Signal2Noise, gene list sorting mode = real, gene list ordering mode = descending, max gene 
set size = 500 (the default), min gene set size = 10 (the default is 15). In addition, the r3 
versus r1 comparisons in data sets 1–3 were investigated according to the gene list sorting 
mode = abs. 
Human tissue samples used for protein expression validation 
Tumours histopathologically classified as GN and NB (data set 5, Table 1) were used for 
immunohistochemistry (4 NB and 4 GN), and immunoblot analysis (4 NB and 5 GN). Tissue 
from patients was obtained during surgery and stored in −80°C. Ethical approval was 
obtained from the Karolinska University Hospital Research Ethics Committee (Approval no. 
2009/1369-31/1 and 03–736). Informed consent for using tumor samples in scientific 
research was provided by parents/guardians. In accordance with the approval from the Ethics 
Committee the informed consent was either written or verbal. When verbal or written assent 
was not obtained the decision was documented in the medical record. 
Immunohistochemistry 
Formalin-fixed and paraffin-embedded (FFPE) tissue slides were deparaffinized in xylol and 
rehydrated in graded alcohols. For antigen retrieval, slides were boiled in a sodium citrate 
buffer (pH 6.0) for 10 min, in a microwave oven. After blocking in 1% bovine serum albumin 
(BSA) for 20 min, the tissue sections were incubated with primary antibody overnight, Sox10 
([N-20], Santa Cruz Biotechnology) and ErbB-3 ([RTJ2], Abcam) respectively, diluted 1:50 
in 1% PBSA. Thereafter slides were rinsed in PBS and endogenous peroxidases were blocked 
in 0.3% H2O2 for 10 min. As a secondary antibody, anti-mouse-horseradish peroxidase 
(HRP) and anti-goat-horseradish peroxidase were used (Invitrogen, Paisley, UK). All slides 
were counterstained with haematoxylin. To control for non-specific binding, antibody 
specific blocking peptides and isotype-matched controls were used. For colocalization studies 
of Erb3 and Sox10, tumor tissue sections were simultaneously stained with primary 
antibodies and for fluorescence visualization, anti-goat Alexa Fluor 594 and anti-mouse 
Alexa Fluor 488 were used, respectively. 
Immunoblot analysis 
Tumours were homogenized in RIPA buffer (20 mM Tris–HCl, pH 7.5, 150 mM NaCl, 1 
mM Na2EDTA, 1 mM EGTA, 1% NP-40, 1% sodium deoxycholate, 2.5 mM sodium 
pyrophosphate, 1 mM beta-glycerophosphate, 1 mM Na3VO4, 1 ug/ml leupeptin) with 
protease inhibitor cocktail (Roche), 42 mM DTT and 1 mM PMSF. The total protein 
concentration was determined using A280 absorbance readings and 100 ug of total protein 
was diluted in NuPAGE ® LDS sample buffer (Invitrogen) with 50 mM DTT and denatured 
for 10 min at 70°C. The samples were then loaded with a prestained Page Ruler protein 
ladder (Thermo-Scientific) on a 4-12% NuPAGE® Bis-Tris polyacrylamide gel (Invitrogen) 
and separated using MOPS buffer at 200V for 50 min. The proteins were transferred to PVDF 
membranes using NuPAGE® transfer buffer (Invitrogen) and 10% methanol. Following 
Ponceau staining to ensure equal loading, membranes were washed with TBS-T (Tris-
buffered saline containing 0.1% Tween 20) and blocked with blocking buffer (5% milk/TBS-
T) for 1h. The primary antibodies were added to the membranes and incubated overnight at 
4°C. The following day, membranes were washed with TBS-T and incubated with secondary 
antibodies. Following final TBS-T washes, protein detection was achieved with Pierce Super 
Signal® West Pico or Femto Chemiluminescent Substrate (Thermo-Scientific). The primary 
antibodies used were anti-ErbB3 [RTJ2] (Abcam, 1:200) and anti-Gapdh (Abcam, #ab8245, 
1:10000). The secondary antibodies used were anti-mouse IgG HRP linked antibodies (Cell 
Signaling, #7076, 1:5000), anti-rabbit IgG HRP linked antibodies (Cell Signaling, #7074, 
1:5000). All antibodies were diluted in blocking buffer. 
Statistical analyses 
The expression relationship of ERBB3 to 1) the discriminative 6-GeneSig (ALK, BIRC5, 
CCND1, MYCN, NTRK1, and PHOX2B) and 2) the ErbB family members EGFR, ERBB2, 
and ERBB4 were tested by a Pearson correlation test. The statistical significance of 
expression levels of ERBB genes (i.e. EGFR, ERBB2, ERBB3, and ERBB4) were investigated 
by Welch t-test. Inter-rater reliability of group assignments was tested by the Kappa statistic 
on crosstabs in SPSS (version 20.0). 
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Additional file 3 GO results. The Biological Networks Gene Ontology tool (BiNGO) in 
Cytoscape was utilized to map the predominant functional themes of the SAM gene lists. The 
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p-value, Description: Description of the gene ontology theme. The 
"DePreterMcArdleWilzén_12_down" list was too short (22 genes) to enable the GO term 
search. 
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Additional file 4 Correlations of ERBB3 to the 6-GeneSig other ERBB family members. 
Left panel: Pearson Correlations of ERBB3 to the 6-gene signature (6-GeneSig) in four data 
sets separately (1 = De Preter, 2 = McArdle/Wilzén, 3 = Wang, 4 = Versteeg). Right panel: 
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Additional file 5 TS candidate genes. Tumour suppressor genes were found by the PubMed 
search term "Neuroblastoma AND tumour suppressor", and from previous mining of 
literature lists according to Vermeulen et al., Lancet Oncol. 2009 July; 10(7): 663–671 (59 
gene set) and Thorell et al., BMC Med Genomics 2009 Aug 17; 2:53. Present in SAMintersect: 
genes found in the intersect SAM lists of data sets 1 & 2. y = yes; n = no. 
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Additional file 6 Gene networks used for GSEA analysis. The table presents the gene 
network members of all c2 curate gene sets (4850 in total) from MSigDB 
(www.broadinstitute.org/gsea/msigdb), and seven ARACNE gene networks used in the 
GSEA analyses. 
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Additional file 7 GSEA results. Results of Gene set enrichment analysis (GSEA) from each 
comparison and each data set are presented in each sheet. Data sets 1–3 (DePreter, 
McArdle/Wilzén, and Wang) comparisons are according to r-subgroups (r1-r4), and data set 4 
(Versteeg) comparisons are according to histopathology groups; Ganglioneuroma (GN), 
Ganglioneuroblastoma (GNB), and Neuroblastoma (NB). Enrichments were run with 1000 
permutations, permutation type = gene set, and gene list sorting mode = real (scoring both 
extremes) in descending order. Results per data set and comparison in each sheet are 
presented as follows: NAME = name of the gene set, SIZE = Size of the gene set, ES = 
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r3 versus r1 comparisons in data sets 1–3 were investigated and presented as gene list sorting 
mode = abs. 
Additional_file_8 as PDF 
Additional file 8 Analyses of the NTRK1 and MYCN gene networks. Networks for MYCN 
(n = 40) and NTRK1 (n = 62) were created from the Wang data set using the ARACNE 
software (see text for details). Differentially expressed genes of r-groups are marked by 
coloured nodes; red = up-regulated, green = down-regulated. Left panel: Data sets 1 and 2 
(DePreter and McArdle/Wilzén) presenting the r3 vs. r1 comparison for the MYCN- (upper) 
and NTRK1- networks (lower). Only genes that were common in both data set 1 and 2 with 
fold change > 2 were included (i.e. SAMintersect gene lists). Middle panel: Data set 3 (Wang) 
presenting the r3 vs. r1 comparison for the MYCN- (upper) and NTRK1- networks (lower). 
Genes included were those present in SAM gene list representing the 1000 most differentially 
expressed with fold change > 2 (ranked after significance). Right panel: Gene set enrichment 
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Additional file 9 The 7-GeneSig classification rules. Rules based on standard deviations 
(SD) of expression values for all samples in each data set. In order to classify samples into 
one of the five subgroups, 5 out of 6 expression rules must be met. Shaded cells indicate rules 
with no exception for classification into that specific subgroup. 
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